# Paradigm Biocapital Advisors LP

> Institutional holdings reported to the SEC as of Q2 2026 on Form 13F. CIK 1855655. Source: https://holderbook.com/funds/1855655-paradigm-biocapital-advisors-lp/

- Reported value: $5.3B
- Positions: 28
- Weight of the ten largest: 75.2%
- Filed: 2026-08-14

A 13F reports long US equity positions only. Short positions, bonds, foreign listings, private holdings and cash are not visible, so this is not the manager's whole book.

## Holdings

| Security | Ticker | Value | Shares | Weight | Quarters held |
|---|---|---|---|---|---|
| REVOLUTION MEDICINES INC | [RVMD](https://holderbook.com/stocks/RVMD/) | $1.2B | 6,361,323 | 22.3% | 10 |
| NUVALENT INC | [NUVL](https://holderbook.com/stocks/NUVL/) | $731.7M | 5,924,433 | 13.7% | 13 |
| EDGEWISE THERAPEUTICS INC | [EWTX](https://holderbook.com/stocks/EWTX/) | $415.1M | 10,215,455 | 7.8% | 10 |
| GENMAB A/S | [GMAB](https://holderbook.com/stocks/GMAB/) | $360.8M | 13,133,131 | 6.8% | 4 |
| SPYRE THERAPEUTICS INC | [SYRE](https://holderbook.com/stocks/SYRE/) | $341.0M | 3,840,778 | 6.4% | 8 |
| APOGEE THERAPEUTICS INC | [APGE](https://holderbook.com/stocks/APGE/) | $209.2M | 1,576,385 | 3.9% | 10 |
| ORUKA THERAPEUTICS INC | [ORKA](https://holderbook.com/stocks/ORKA/) | $204.1M | 2,144,526 | 3.8% | 3 |
| TANGO THERAPEUTICS INC | [TNGX](https://holderbook.com/stocks/TNGX/) | $198.7M | 6,357,523 | 3.7% | 2 |
| BELITE BIO INC | [BLTE](https://holderbook.com/stocks/BLTE/) | $189.8M | 1,232,877 | 3.6% | 2 |
| ERASCA INC | [ERAS](https://holderbook.com/stocks/ERAS/) | $175.0M | 9,550,000 | 3.3% | 9 |
| TARSUS PHARMACEUTICALS INC | [TARS](https://holderbook.com/stocks/TARS/) | $174.7M | 2,775,649 | 3.3% | 11 |
| ALNYLAM PHARMACEUTICALS INC | [ALNY](https://holderbook.com/stocks/ALNY/) | $144.5M | 480,000 | 2.7% | 1 |
| INSMED INC | [INSM](https://holderbook.com/stocks/INSM/) | $141.4M | 1,325,977 | 2.6% | 2 |
| MBX BIOSCIENCES INC | [MBX](https://holderbook.com/stocks/MBX/) | $138.4M | 2,508,015 | 2.6% | 1 |
| VAXCYTE INC | [PCVX](https://holderbook.com/stocks/PCVX/) | $123.7M | 2,127,852 | 2.3% | 10 |
| VIRIDIAN THERAPEUTICS INC | [VRDN](https://holderbook.com/stocks/VRDN/) | $123.5M | 6,723,788 | 2.3% | 19 |
| OLEMA PHARMACEUTICALS INC | [OLMA](https://holderbook.com/stocks/OLMA/) | $108.5M | 8,670,576 | 2.0% | 14 |
| JADE BIOSCIENCES INC | [JBIO](https://holderbook.com/stocks/JBIO/) | $63.5M | 2,857,405 | 1.2% | 1 |
| TYRA BIOSCIENCES INC | [TYRA](https://holderbook.com/stocks/TYRA/) | $58.4M | 1,828,607 | 1.1% | 2 |
| ASSEMBLY BIOSCIENCES INC | [ASMB](https://holderbook.com/stocks/ASMB/) | $42.7M | 1,553,748 | 0.8% | 3 |
| EYEPOINT INC | [EYPT](https://holderbook.com/stocks/EYPT/) | $41.3M | 2,890,397 | 0.8% | 4 |
| ACHIEVE LIFE SCIENCE INC | [ACHV](https://holderbook.com/stocks/ACHV/) | $32.3M | 4,951,856 | 0.6% | 1 |
| VOR BIOPHARMA INC | [VOR](https://holderbook.com/stocks/VOR/) | $32.2M | 1,750,000 | 0.6% | 3 |
| MAPLIGHT THERAPEUTICS INC | [MPLT](https://holderbook.com/stocks/MPLT/) | $24.6M | 685,852 | 0.5% | 1 |
| KARDIGAN INC | [KARD](https://holderbook.com/stocks/KARD/) | $21.5M | 900,000 | 0.4% | 1 |
| LEXEO THERAPEUTICS INC | [LXEO](https://holderbook.com/stocks/LXEO/) | $19.4M | 4,175,382 | 0.4% | 3 |
| EDITAS MEDICINE INC | [EDIT](https://holderbook.com/stocks/EDIT/) | $18.1M | 5,586,625 | 0.3% | 1 |
| INVENTIVA SA | [IVA](https://holderbook.com/stocks/IVA/) | $15.1M | 4,000,000 | 0.3% | 3 |

## What the disclosed book did

Not the fund's return. This is the change in value of the positions disclosed on Form 13F, had they been left untouched, against SPY over the same quarter ends.

| Quarter | Book | Market | Difference | Priced |
|---|---|---|---|---|
| Q2 2026 | +27.3% | +14.8% | +12.4% | 81% |
| Q1 2026 | +14.0% | -4.6% | +18.6% | 96% |
| Q4 2025 | +24.5% | +2.4% | +22.2% | 99% |
| Q3 2025 | +31.0% | +7.8% | +23.2% | 99% |
| Q2 2025 | -0.3% | +10.5% | -10.8% | 99% |
| Q1 2025 | -19.4% | -4.6% | -14.9% | 100% |
| Q4 2024 | -10.3% | +2.1% | -12.5% | 97% |
| Q3 2024 | +17.3% | +5.4% | +11.9% | 96% |

## Quarter by quarter

| Quarter | Value | Positions |
|---|---|---|
| Q2 2026 | $5.3B | 28 |
| Q1 2026 | $4.9B | 35 |
| Q4 2025 | $3.9B | 30 |
| Q3 2025 | $3.5B | 34 |
| Q2 2025 | $2.3B | 28 |
| Q1 2025 | $2.2B | 27 |
| Q4 2024 | $2.9B | 28 |
| Q3 2024 | $3.0B | 31 |
| Q2 2024 | $2.6B | 35 |
| Q1 2024 | $2.8B | 34 |
| Q4 2023 | $2.1B | 29 |
| Q3 2023 | $1.5B | 30 |